SEARCH RESULTS FOR:

Abraham Klip Moshinsky

DIRECTOR GENERAL, UNIGEL MEXICO
Unigel outlines the current focus of its Mexican subsidiary, Plastiglas.

Eugenio Manzano

EXECUTIVE DIRECTOR, POCHTECA
Pochteca identifies key trends in the Latin American chemical distribution sector.

Mustafa Rawji

MANAGING DIRECTOR, RAWBANK
"DRC banks are in a relatively good financial position, with total deposits in the banking system at around US$14 billion and total lending at US$4-5 billion."

Marcus Carlson

COUNTRY MANAGER DRC, EPIROC
"It is important for us is to innovate through zero emission products and continue to play a key role in the automatization of the industry."

Federico De Simone

DIRECTOR, DE SIMONE GROUP
MACIG West Africa 2021-2022
"The high raw material prices create a two-sided situation whereby some economies are helped by the high prices, while some sectors suffer due to heightened costs."

Jay Shukla

PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS, INC.
"Nivagen has excellent connections and market access, and we are always looking to in-license FDA-approved products that leverage our expertise in launching in the US market."

Debbie Hart

PRESIDENT & CEO, BIONJ
"With nearly 40% of all new FDA approvals over the last two years coming from companies with a footprint in NJ, our state continues to lead the way in bringing new therapies and cures to patients."

Laurie M. Clark

FOUNDER AND CEO, ONYEN CORPORATION
"ESG is ethically and financially necessary for companies in the current environment, so we wanted to help them navigate the complexities of reporting."

Stefan Spears

CHAIRMAN AND CEO, INVENTUS MINING CORP.
"Our focus remains on precious metals, but in some of our drilling, cobalt, copper and nickel contribute a significant portion of the metal value."

Timothy Beale

DIRECTOR, PAMPA METALS
Timonthy Beale outlines Pampa Metals exploration plans in Chile for 2022

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS